Jignesh Veragiwala
Family Medicine · Guthrie, OKNPI 1275567513
Payments from drug & device makers
Across 263 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$829
- Novo Nordisk$779
- Lilly USA, LLC$428
- GSK$343
- AbbVie$263
- Amarin Pharma, Inc.$194
- plus $1K from 27 others
What the payments were for
- Food & beverage$4,230100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 58 | $829 |
| Novo Nordisk | 54 | $779 |
| Lilly USA, LLC | 27 | $428 |
| GSK | 22 | $343 |
| AbbVie(2 entities) | 14 | $263 |
| Amarin Pharma, Inc. | 11 | $194 |
| Merck | 13 | $181 |
| AstraZeneca(2 entities) | 5 | $177 |
| Boehringer Ingelheim | 9 | $144 |
| Genentech USA, Inc. | 6 | $113 |
| Exact Sciences | 5 | $85 |
| Biogen | 5 | $77 |
| Mylan Specialty L.p. | 4 | $73 |
| Bayer | 3 | $53 |
| Astellas Pharma US Inc | 2 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $46 |
| Novartis | 2 | $42 |
| Nabriva Therapeutics, PLC | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Abbott | 2 | $31 |
| Amgen | 2 | $29 |
| Dexcom, Inc. | 2 | $28 |
| Lundbeck LLC | 1 | $27 |
| Eisai Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Medtronic | 1 | $16 |
| Evofem Biosciences, Inc. | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$114
How this compares
$4,230 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 295 | $139,062 |
| OzempicSemaglutide | 94 | $114,990 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $69,785 |
| JanuviaSitagliptin Phosphate | 74 | $46,404 |
| XareltoRivaroxaban | 112 | $39,348 |
| JardianceEmpagliflozin | 57 | $37,566 |
| MounjaroTirzepatide | 20 | $34,628 |
| Breo ElliptaFluticasone/Vilanterol | 55 | $23,040 |
| FarxigaDapagliflozin Propanediol | 27 | $20,546 |
| MyrbetriqMirabegron | 57 | $14,679 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 29 | $14,299 |
| LinzessLinaclotide | 19 | $13,314 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $11,917 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $11,624 |
| Atorvastatin Calcium | 829 | $11,139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $829 | $139,062295 claims |
| Novo NordiskOzempic | $779 | $114,99094 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $343 | $112,794189 claims |
| MerckJanuvia | $181 | $46,40474 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $144 | $43,15169 claims |
| Johnson & JohnsonXarelto | $19 | $39,348112 claims |
| Lilly USA, LLCMounjaro | $428 | $34,62820 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $177 | $32,46445 claims |
| AbbVieLinzess, Lumigan | $263 | $16,84032 claims |
| Astellas Pharma US IncMyrbetriq | $47 | $14,67957 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $46 | $7,58224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Guthrie
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.